DMA Diamedica Therapeutics

DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, has
been invited to present at the 25th Annual Piper Jaffray Healthcare Conference,
which will be held in New York December 3-4, 2013. DiaMedica's Chairman and
Chief Executive Officer, Rick Pauls, will be presenting on Tuesday, December 3,
at 1:50 p.m. ET. 


The goal of Piper Jaffray's 25th Annual Healthcare Conference is to bring
together key industry executives, investors and Piper professionals to provide
multiple perspectives, investigate critical trends and identify the leaders in
the markets that are driving our economy. The conference will be held at The New
York Palace - New York.


About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein
that represents a novel approach to treating diabetes and associated
complications. DiaMedica is also developing a novel monoclonal antibody, DM204
for the treatment of Type 2 diabetes, which is in preclinical development. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Rick Pauls
Chairman & CEO
DiaMedica Inc.
763-710-4455
info@diamedica.com

DiaMedica Inc. (TSXV:DMA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

DiaMedica Inc. (TSXV:DMA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024